Kura Oncology Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
KURA$7.57+4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(In thousands)
| Accumulated | |||||||
|---|---|---|---|---|---|---|---|
| Additional · Other · Total | |||||||
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | |||||||
| Shares · Par Value · Capital · Income (Loss) · Deficit · Equity | |||||||
| Balance as of December 31, 2021 | 66,572 | $7 | $941,359 | $(1,789) | $(432,968) | $506,609 | |
| Issuance of common stock, net of offering costs | 1,370 | — | 24,721 | — | — | 24,721 | |
| Share-based compensation expense | — | — | 26,318 | — | — | 26,318 | |
| Issuance of common stock under equity plans | 372 | — | 4,419 | — | — | 4,419 | |
| Issuance of warrants in connection with debt facility | — | — | 294 | — | — | 294 | |
| Other comprehensive loss | — | — | — | (6,243) | — | (6,243) | |
| Net loss | — | — | — | — | (135,840) | (135,840) | |
| Balance as of December 31, 2022 | 68,314 | 7 | 997,111 | (8,032) | (568,808) | 420,278 | |
| Issuance of common stock, net of offering costs | 5,661 | — | 60,919 | — | — | 60,919 | |
| Issuance of pre-funded warrants to purchase common stock, net of offering costs | — | — | 32,658 | — | — | 32,658 | |
| Share-based compensation expense | — | — | 28,082 | — | — | 28,082 | |
| Issuance of common stock under equity plans | 375 | — | 1,206 | — | — | 1,206 | |
| Other comprehensive income | — | — | — | 6,761 | — | 6,761 | |
| Net loss | — | — | — | — | (152,631) | (152,631) | |
| Balance as of December 31, 2023 | 74,350 | 7 | 1,119,976 | (1,271) | (721,439) | 397,273 | |
| Issuance of common stock, net of offering costs | 1,377 | — | 23,087 | — | — | 23,087 | |
| Issuance of pre-funded warrants to purchase common stock, net of offering costs | — | — | 122,726 | — | — | 122,726 | |
| Share-based compensation expense | — | — | 33,897 | — | — | 33,897 | |
| Exercise of pre-funded warrants | 1,420 | 1 | — | 1 | |||
| Issuance of common stock under equity plans | 1,082 | — | 8,604 | — | — | 8,604 | |
| Other comprehensive income | — | — | — | 2,035 | — | 2,035 | |
| Net loss | — | — | — | — | (173,983) | (173,983) | |
| Balance as of December 31, 2024 | 78,229 | $8 | $1,308,290 | $764 | $(895,422) | $413,640 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.